Minodronic acid
- CAS NO.:180064-38-4
- Empirical Formula: C9H12N2O7P2
- Molecular Weight: 322.15
- MDL number: MFCD00890772
- EINECS: 1592732-453-0
- SAFETY DATA SHEET (SDS)
- Update Date: 2024-06-06 16:20:44
What is Minodronic acid?
Description
Minodronic acid hydrate, a third-generation bisphosphonate, was
approved and launched in Japan for the oral treatment of
osteoporosis. Osteoporosis is a skeletal disorder characterized by low bone mass and structural deterioration of bone tissue resulting in bone
fragility and increased susceptibility to fractures, particularly of the hip,
spine, and wrist. It is the most common type of metabolic bone disease
and a major health concern affecting 200 million women worldwide.
Minodronic acid is the newest nitrogen-containing bisphosphonate to reach the market. In vitro, it inhibits
recombinant human FPP synthase activity with similar potency as zoledronic acid (IC50 = 3 nM for both agents).
The most common adverse events associated with minodronic acid included stomach and abdominal discomfort, abdominal pain, decrease in blood calcium level, and gastritis. The chemical synthesis of minodronic acid starts with a condensation reaction of 2-aminopyridine with ethyl 4-bromo-3-oxobutyrate by means of sodium bicarbonate to produce 2-(imidazo[1,2-a]pyridin-3-yl)acetic acid ethyl ester, which is hydrolyzed to the corresponding carboxylic acid with potassium hydroxide. Treatment of the carboxylic acid intermediate with phosphorus acid and phosphorus trichloride followed by hydrolysis with hydrochloric acid gives minodronic acid.
Originator
Astellas Pharma (Japan)
The Uses of Minodronic acid
Minodronic acid is developed for osteoporosis treatment.
brand name
Recalbon, Bonoteo
Properties of Minodronic acid
Density | 1.97±0.1 g/cm3(Predicted) |
storage temp. | under inert gas (nitrogen or Argon) at 2-8°C |
solubility | Aqueous Base (Slightly), Methanol (Slightly) |
pka | 1.48±0.10(Predicted) |
form | Solid |
color | White to Off-White |
Safety information for Minodronic acid
Signal word | Warning |
Pictogram(s) |
Exclamation Mark Irritant GHS07 |
GHS Hazard Statements |
H302:Acute toxicity,oral |
Precautionary Statement Codes |
P280:Wear protective gloves/protective clothing/eye protection/face protection. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing. |
Computed Descriptors for Minodronic acid
New Products
6-Bromo 2-Iodo Indole Pyridine 2,4,6-Tricarboxaldehyde Ivermectin EP Impurity B Fosfomycin EP impurity D Rimegepant Impurity 3 Tubulysin G Tubulysin C (R)-tert-butyl (4-methyl-1-oxopentan-3-yl)carbamate Tubulysin M Imeglimin Hydrochloride IH 2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]ethanol ethanedioate (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine Calcium Sodium Phosphosilicate IH 2-(1-(Mercaptomethyl) cyclopropyl) acetonitrile 2-[2-[3(S)-3[2-(7-chloro-2-quinolinyl) ethenyl] phenyl-3- hydroxyl propyl] phenyl]-2-propanol 2-(4-Bromopyridin-2-yl)acetonitrile 1-(4-Aminophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one 4,7-Dibromobenzo[c][1,2,5]thiadiazole-5,6-diamine 4,8-dibromo-5H-[1,2,3]triazolo[4',5':4,5]benzo[1,2-c][1,2,5]thiadiazole Methyl 4-amino-3-(piperidin-1-yl)benzoate 3,6-Bis(4-iodophenyl)-2,5-dihydropyrrolo[3,4-c]pyrrole-1,4-dione 4-Methoxy-2,3-dihydro-1H-inden-1-one 4-bromo-7H-pyrrolo[2,3-d]pyrimidine 5-bromo-3-iodopyridin-2-olRelated products of tetrahydrofuran
You may like
-
Minodronic acid 95% CAS 180064-38-4View Details
180064-38-4 -
3,6-Bis(4-iodophenyl)-2,5-dihydropyrrolo[3,4-c]pyrrole-1,4-dioneView Details
952145-70-9 -
1262243-12-8View Details
1262243-12-8 -
Sidchem 730View Details
-
Sidchem BT 20View Details
-
1572177-89-9View Details
1572177-89-9 -
6390-09-6View Details
6390-09-6 -
6-Bromo indoleView Details